Teriparatide may accelerate the growth of a pre‑existing malignant tumor in an elderly patient with osteoporosis: A case report
- Tetsuya Ogawa
- Shusa Ohshika
- Michiro Yanagisawa
- Akira Kurose
- Yasuyuki Ishibashi
Affiliations: Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan, Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan
- Published online on: December 16, 2019 https://doi.org/10.3892/mco.2019.1966
Copyright: © Ogawa
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The present report describes a case in which teriparatide, which is widely used to treat osteoporosis, may have accelerated the growth of an undiagnosed pre‑existing bone tumor of the femur. A 76‑year‑old woman visited hospital with pain in the right thigh after falling from a ladder. A non‑pathological femoral shaft fracture was diagnosed by plain radiography. There were no findings of pathological fracture on the examination. In addition, the patient underwent intramedullary femoral nail fixation and started teriparatide treatment for osteoporosis. The teriparatide was discontinued after 2 months due to nausea. A total of 6 months after surgery, the woman visited Hirosaki University Hospital with abnormal swelling of the right thigh. Following a diagnosis of high‑grade malignant mesenchymal bone tumor by needle biopsy, the patient underwent right hip disarticulation. Pathological examination provided a definitive diagnosis of osteoblastic osteosarcoma. The present case is a reminder that teriparatide may accelerate the growth of a pre‑existing malignant tumor and that fractures, particularly in elderly patients, should be screened for pathological fracture prior to administering teriparatide.